Literature DB >> 9417492

[Selenium substitution in acute myocardial infarct].

R Thiele1, D Wagner, M Gassel, K Winnefeld, J Pleissner, R Pfeifer.   

Abstract

BACKGROUND: Previous examinations have demonstrated decreased selenium levels in serum and full blood in patients with myocardial infarction. PATIENTS AND
METHOD: 28 patients received a selenium treatment additional to the usual treatment of myocardial infarction. 19 patients with myocardial infarction with no supplementary selenium treatment served as a control group. Selenium levels in serum, full blood and urine were measured and the complications of the myocardial infarction documanted.
RESULTS: There was a significant increase of serum and full blood selenium and glutathione peroxidase levels under i.v. selenium therapy in the acute phase of myocardial infarction (first to third day). Left heart failure more rarely occurred in the selenium group (20%) than in control patients (57%). Acute tachycardial cardiac rhythm disturbances such as ventricular extrasystoles and couplets diminished in both groups; ventricular extrasystoles decreased in the selenium group.
CONCLUSIONS: Selen should be substituted in patients with acute myocardial infarction and decreased selen levels. It would be useful to carry out a prospective double-blind study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9417492     DOI: 10.1007/bf03041957

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  7 in total

1.  [Selenium--an essential trace element].

Authors:  B Tiran
Journal:  Wien Klin Wochenschr       Date:  1997-01-17       Impact factor: 1.704

2.  Trace elements and myocardial infarction, an autopsy study from western Norway.

Authors:  O Ringdal; K J Andersen; E Svendsen; K Julshamn
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986

3.  Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.

Authors:  D E Paglia; W N Valentine
Journal:  J Lab Clin Med       Date:  1967-07

4.  Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study.

Authors:  J T Salonen; G Alfthan; J K Huttunen; J Pikkarainen; P Puska
Journal:  Lancet       Date:  1982-07-24       Impact factor: 79.321

5.  Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men.

Authors:  J T Salonen; R Salonen; K Seppänen; M Kantola; M Parviainen; G Alfthan; P H Mäenpää; E Taskinen; R Rauramaa
Journal:  Atherosclerosis       Date:  1988-03       Impact factor: 5.162

6.  Serum selenium, glutathione peroxidase activity and high-density lipoprotein cholesterol--effect of selenium supplementation.

Authors:  P V Luoma; E A Sotaniemi; H Korpela; J Kumpulainen
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-12

7.  The serum selenium concentration of patients with acute myocardial infarction.

Authors:  O Oster; M Drexler; J Schenk; T Meinertz; W Kasper; C J Schuster; W Prellwitz
Journal:  Ann Clin Res       Date:  1986
  7 in total
  3 in total

1.  [Effect of administration of selenium and vitamin E on heart failure and ventricular arrhythmias in patients with acute myocardial infarct].

Authors:  P Tränkmann; R Thiele; K Winnefeld; K Seliger
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 2.  Selenium supplementation for critically ill adults.

Authors:  Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2015-07-27

3.  Selenium Treatment and Chagasic Cardiopathy (STCC): study protocol for a double-blind randomized controlled trial.

Authors:  Pedro Emmanuel Alvarenga Americano do Brasil; Andréa Pereira de Souza; Alejandro Marcel Hasslocher-Moreno; Sérgio Salles Xavier; Sonia Regina Lambert Passos; Maria de Fátima Ramos Moreira; Marília Santini de Oliveira; Gilberto Marcelo Sperandio da Silva; Roberto Magalhães Saraiva; Claudia Santos de Aguiar Cardoso; Andréa Silvestre de Sousa; Mauro Felippe Felix Mediano; Maria da Gloria Bonecini de Almeida; Otacílio da Cruz Moreira; Constança Britto; Tania Cremonini de Araújo-Jorge
Journal:  Trials       Date:  2014-10-06       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.